WO2025114862 - IL-33 BINDING ANTIBODIES
National phase entry is expected:
Publication Number
WO/2025/114862
Publication Date
05.06.2025
International Application No.
PCT/IB2024/061799
International Filing Date
25.11.2024
Title **
[English]
IL-33 BINDING ANTIBODIES
[French]
ANTICORPS SE LIANT À IL-33
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
ORECCHIA, Martin
EDWARDS, Matthew
BEATON, Andrew
HOOK, Laura
DIXON, David
GUO, Xieyang
CHUNG, Chun-wa
Priority Data
63/602,704
27.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3746 | |
| EPO | Filing, Examination, Granting | 24148 | |
| Japan | Filing, Examination, Granting | 2884 | |
| South Korea | Filing, Examination, Granting | 3491 | |
| USA | Filing, Examination, Granting | 14640 |
Total:
48,909
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to the treatment of interleukin 33 (IL-33) mediated diseases, including lung diseases. In particular, the present disclosure relates to IL-33 binding proteins, including anti-IL-33 antibodies, and their uses in the treatment of IL-33 mediated diseases.[French]
La présente divulgation concerne le traitement de maladies médiées par l'interleukine 33 (IL-33), y compris des maladies pulmonaires. En particulier, la présente divulgation concerne des protéines de liaison à IL-33, comprenant des anticorps anti-IL-33, et leurs utilisations dans le traitement de maladies médiées par IL-33.